Long-term Remission of Atopic Dermatitis after Discontinuation of Dupilumab
DOI:
https://doi.org/10.2340/actadv.v102.295Abstract
Abstract is missing (Short communication)
Downloads
References
Katoh N, Ohya Y, Ikeda M, Ebihara T, Katayama I, Saeki H, et al. Japanese guidelines for atopic dermatitis 2020. Allergol Int 2020; 69: 356-369.
https://doi.org/10.1016/j.alit.2020.02.006 DOI: https://doi.org/10.1016/j.alit.2020.02.006
de Wijs LEM, Fujimoto RFT, Andrinopoulou ER, Nijsten T, Hijnen D, Kataoka Y. Dupilumab treatment in patients with atopic dermatitis: a comparative cohort study between the Netherlands and Japan shows a discrepancy in patient-reported outcome measures. Br J Dermatol 2021; 185: 555-562.
https://doi.org/10.1111/bjd.19897 DOI: https://doi.org/10.1111/bjd.19897
Treister AD, Lio PA. Remittive effect of dupilumab in atopic dermatitis. Dermatol Ther 2018; 31: e12711.
https://doi.org/10.1111/dth.12711 DOI: https://doi.org/10.1111/dth.12711
Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis a randomized clinical trial. JAMA Dermatol 2020; 156: 131-143.
https://doi.org/10.1001/jamadermatol.2019.3617 DOI: https://doi.org/10.1001/jamadermatol.2019.3617
Granlund H, Erkko P, Sinisalo M, Reitamo S. Cyclosporin in atopic dermatitis: time to relapse and effect of intermittent therapy. Br J Dermatol 1995; 132: 106-112.
https://doi.org/10.1111/j.1365-2133.1995.tb08633.x DOI: https://doi.org/10.1111/j.1365-2133.1995.tb08633.x
Silverberg JI, Guttman-Yassky E, Gadkari A, Kuznik A, Mallya UG, Mastey V, et al. Real-world persistence with dupilumab among adults with atopic dermatitis. Ann Allergy Asthma Immunol 2021; 126: 40-45.
https://doi.org/10.1016/j.anai.2020.07.026 DOI: https://doi.org/10.1016/j.anai.2020.07.026
Kovalenko P, Davis JD, Li M, Rippley R, Ardeleanu M, Shumel B, et al. Base and covariate population pharmacokinetic analyses of dupilumab using Phase 3 data. Clin Pharmacol Drug Dev 2020; 9: 756-767.
https://doi.org/10.1002/cpdd.780 DOI: https://doi.org/10.1002/cpdd.780
Eshtiaghi P, Gooderham MJ. Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis. Core Evid 2018; 13: 13-20.
https://doi.org/10.2147/CE.S133661 DOI: https://doi.org/10.2147/CE.S133661
Imai Y, Kusakabe M, Nagai M, Yasuda K, Yamanishi K. Dupilumab effects on innate lymphoid cell and helper T cell populations in patients with atopic dermatitis. JID Innov 2021; 1: 100003.
https://doi.org/10.1016/j.xjidi.2021.100003 DOI: https://doi.org/10.1016/j.xjidi.2021.100003
Published
How to Cite
License
Copyright (c) 2022 Shoko Miyamoto, Yasutomo Imai, Masaru Natsuaki, Kiyofumi Yamanishi, Nobuo Kanazawa
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
